Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02246673 · ClinicalTrials.gov registry record · Phase 2
RDEA3170 and Febuxostat Combination Study in Gout Subjects
A Phase 2 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT02246673 is a Phase 2 study that has completed, run by Ardea Biosciences. The registered enrollment target is 64 participants.
The verdict
NCT02246673, a Phase 2 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
Interventions
- DRUG RDEA3170 5 mg
- DRUG RDEA3170 10 mg
- DRUG Febuxostat 40 mg
- DRUG RDEA3170 15 mg
- DRUG RDEA3170 2.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02246673
The ClinicalTrials.gov registry entry for NCT02246673 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which RDEA3170 5 mg is the first listed.
NCT02246673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02246673 about?
NCT02246673 is a clinical study titled "RDEA3170 and Febuxostat Combination Study in Gout Subjects". This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
What is the current status of trial NCT02246673?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2014-10. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02246673?
The interventions under investigation include: RDEA3170 5 mg (DRUG), RDEA3170 10 mg (DRUG), Febuxostat 40 mg (DRUG), RDEA3170 15 mg (DRUG), RDEA3170 2.5 (DRUG).
Who is sponsoring clinical trial NCT02246673?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.